HVC-796 News
Most Popular HVC-796 Story
Wyeth, ViroPharma drops Hep C drug
After observing serious safety problems in a Phase II trial, Wyeth and ViroPharma are dropping development of HCV-796. In August the companies halted study of the drug when the data showed elevated... Read more...
Latest Headlines
- April 17, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
